Treatment of Alzheimer’s disease in the long-term-care setting
- 15 May 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (10) , 899-907
Abstract
Purpose. Pharmacologic treatment for patients with Alzheimer’s disease (AD) who reside in long-term-care (LTC) facilities is discussed. Summary. The recognition of AD can be problematic in patients residing in LTC who do not have a preexisting diagnosis of dementia. Residents in LTC facilities generally have fewer day-to-day cognitive demands, and, thus, nursing staff or caregivers may not recognize cognitive deficits until the disease is more advanced. The current therapeutic options for the treatment of AD are the cholinesterase inhibitors (ChEIs) and the N-methyl-d-aspartate receptor antagonist memantine. The ChEIs rivastigmine and galantamine are currently approved for the treatment of mild-to-moderate AD, and memantine is approved for the treatment of moderate-to-severe AD. The ChEI donepezil is presently approved for the treatment of mild, moderate, and severe AD in the United States. Two placebo-controlled trials in nursing-home patients receiving donepezil have been published. In both studies, donepezil appeared to be safe and effective for the treatment of AD in patients residing in LTC facilities. Data from an open-label study suggest that rivastigmine treatment might also provide benefits in nursing-home patients with moderate-to-severe AD. Another study demonstrated that treatment with galantamine might delay the need for transfer from an assisted-living facility to a nursing home. The effectiveness and safety of memantine have been assessed in a subgroup of patients with severe AD residing in LTC facilities. There were no major differences in safety and tolerability between the active treatment group and placebo. The relative and clinical importance of the cognitive, functional, and behavioral changes observed in LTC patients treated with ChEIs and memantine remain to be identified. Conclusion. Pharmacologic treatment should be recommended for most patients with AD who reside in LTC facilities.Keywords
This publication has 46 references indexed in Scilit:
- EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*International Journal Of Clinical Practice, 2007
- Dementia in Subjects Aged 75 Years or Over within the PAQUID Cohort: Prevalence and Burden by SeverityDementia and Geriatric Cognitive Disorders, 2006
- 3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous TherapyDementia and Geriatric Cognitive Disorders, 2006
- Improved Evaluation and Management of Cognitive Impairment: Results of a Comprehensive Intervention in Long-term CareJournal of the American Medical Directors Association, 2006
- Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer??s Disease and Other DementiasPharmacoEconomics, 2006
- Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label studyCurrent Medical Research and Opinion, 2004
- Diagnosing Dementia in Long-Term Care FacilitiesJournal of the American Medical Directors Association, 2003
- The recognition of dementia in ‘non‐EMI’ nursing home residents in South East EnglandInternational Journal of Geriatric Psychiatry, 2003
- The Neuropsychiatric InventoryNeurology, 1994
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984